TNBC response to CDK4/6 inhibitors plus RANKL inhibitors

CDK4/6i alone have proven to be largely ineffective in TNBC, even in the presence of functional retinoblastoma protein (pRB). In this study, we investigated the role of the RANK pathway in the response to CDK4/6i in pRB-proficient TNBC. Transcriptomic analysis of xenografts revealed that combining CDK4/6i with RANKLi more effectively arrested the cell cycle. Overall design: The transcriptomic profiles of tumor tissue from MDA-MB-231 xenografts implanted in NSG mice, collected after 21 days of treatment with Vehicle, OPG-Fc, Palbociclib or Palbociclib+OPG-Fc, were analyzed by RNASeq. 2-3 tumors per group were included.